Brain Cancer

With low survival rates primary brain cancers such as glioblastoma multiforme (the most common and aggressive of malignant brain tumours) are among the deadliest forms of cancer. Drug development activity is therefore intense in this sector, with resulting business development opportunities. Reports in the Brain Cancer section enable you to explore various facets of the industry from a variety of expert viewpoints, including R&D (clinical trials, drug discovery, etc.), competitive landscape, supply and demand, regional markets, regional market analysis, and much more. Show Less ... more

• Brain Cancer Drug Pipeline Update 2013

  EURO€ 1,499.00USD$ 1,950.00GBP£ 1,261.00AUD$ 1,907.00JPY¥ 192,545.00SEK 12 804,00CHF 1'838.00CAD$ 1,987.00 Bioseeker, Apr 2013
  Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases...

• 09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 153.00USD$ 199.00GBP£ 129.00AUD$ 195.00JPY¥ 19,648.00SEK 1 307,00CHF 188.00CAD$ 203.00 Life Science Intelligence, Sep 2012
  This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in September 2012 All companies include technology, market(s), key...

• Chinese Markets for Brain Cancer Treatment Drugs

  EURO€ 4,280.00USD$ 4,000.00GBP£ 2,432.00AUD$ 5,823.00JPY¥ 490,826.00SEK 34 516,00CHF 5'745.00CAD$ 5,347.00 AMID Co, Sep 2012 , Pages: 200
  China's demand for brain cancer treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

• 06 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Jun 2012 , Pages: 40
  This report includes details on 39 emerging medical technology companies that have been identified by LSI's in-house research team in June 2012 All companies include technology, market(s), key executive,...

• 05 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, May 2012 , Pages: 45
  This report includes details on 41 emerging medical technology companies that have been identified by LSI's in-house research team in May 2012 All companies include technology, market(s), key executive,...

• 04- 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Apr 2012 , Pages: 38
  This report includes details on 37 emerging medical technology companies that have been identified by LSI's in-house research team in April 2012 All companies include technology, market(s), key executive,...

• 03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Mar 2012 , Pages: 81
  This report includes details on 61 emerging medical technology companies that have been identified by LSI's in-house research team in March 2012 All companies include technology, market(s), key executive,...

• 02 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Feb 2012 , Pages: 95
  This report includes details on 43 emerging medical technology companies that have been identified by LSI's in-house research team in February 2012 All companies include technology, market(s), key executive,...

• Global Brain Cancer Drug Pipeline Capsule - 2012

  EURO€ 361.00USD$ 470.00GBP£ 304.00AUD$ 460.00JPY¥ 46,405.00SEK 3 086,00CHF 443.00CAD$ 479.00 Fore Pharma, Jan 2012 , Pages: 15
  Fore Pharma’s latest report ‘Global Brain Cancer Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global Brain Cancer drug market. It covers...

• Charge Cards In Russia

  EURO€ 692.00USD$ 900.00GBP£ 582.00AUD$ 880.00JPY¥ 88,860.00SEK 5 909,00CHF 848.00CAD$ 917.00 Euromonitor International, Jan 2012 , Pages: 27
  Pre-paid fleet cards became increasingly popular in Russia during the review period, although these cards do not yet have a credit function. Only relatively few players—usually small lenders and regional...

• 01 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Jan 2012 , Pages: 101
  This report includes details on 47 emerging medical technology companies that have been identified by LSI's in-house research team in January 2012 All companies include technology, market(s), key executive,...

• Brain Cancer Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Aug 2011 , Pages: 120
  Brain Cancer Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Brain Cancer Global Clinical Trials Review, H2, 2011" provides data on the Brain Cancer clinical trial...

• 2011 Global Markets for External Radiation Therapy

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Life Science Intelligence, May 2011 , Pages: 129
  2011 Global Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

• 2011 O.U.S. Markets For External Radiation Therapy

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, May 2011 , Pages: 84
  2011 O U S Markets For External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

• 2011 U.S. Markets for External Radiation Therapy

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, May 2011 , Pages: 66
  2011 U S Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data -...

• Global Neurosurgical Product Markets

  EURO€ 5,377.00USD$ 6,995.00GBP£ 4,524.00AUD$ 6,842.00JPY¥ 690,637.00SEK 45 928,00CHF 6'593.00CAD$ 7,128.00 Life Science Intelligence, Mar 2009 , Pages: 193
  Common conditions necessitating the use of neurosurgical products include hydrocephalus, aneurysms, arteriovenous malformations (AVMs), and pituitary and intracranial tumors Intracranial shunts are...

• Cancer - Brain Tumor

  EURO€ 1,149.00USD$ 1,495.00GBP£ 967.00AUD$ 1,462.00JPY¥ 147,606.00SEK 9 816,00CHF 1'409.00CAD$ 1,523.00 Life Science Analytics, Mar 2008 , Pages: 165
  Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area The latest news, by company, also ensures that each report...

• European Head and Neck Cancer Therapeutics Markets

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Frost & Sullivan, Aug 2007 , Pages: 124
  This Frost & Sullivan research service titled European Head and Neck Cancer Therapeutics Markets provides market drivers, restraints and revenue forecasts for this market In this research, Frost & Sullivan's...